» Authors » Adam D Durbin

Adam D Durbin

Explore the profile of Adam D Durbin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 43
Citations 1644
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Gustafson A, Durbin A, Artinger K, Ford H
Front Cell Dev Biol . 2025 Feb; 12:1521523. PMID: 39902277
Rhabdomyosarcoma is a soft-tissue sarcoma that occurs most frequently in pediatric patients and has poor survival rates in patients with recurrent or metastatic disease. There are two major sub-types of...
2.
Ritter K, Durbin A
Cold Spring Harb Perspect Med . 2024 May; PMID: 38806246
The quest for effective cancer therapeutics has traditionally centered on targeting mutated or overexpressed oncogenic proteins. However, challenges arise in cancers with low mutational burden or when the mutated oncogene...
3.
Shendy N, Bikowitz M, Sigua L, Zhang Y, Mercier A, Khashana Y, et al.
Nat Commun . 2024 Apr; 15(1):3483. PMID: 38664416
Chemical discovery efforts commonly target individual protein domains. Many proteins, including the EP300/CBP histone acetyltransferases (HATs), contain several targetable domains. EP300/CBP are critical gene-regulatory targets in cancer, with existing high...
4.
Abu-Zaid A, Fang J, Jin H, Singh S, Pichavaram P, Wu Q, et al.
Cell Rep Med . 2024 Mar; 5(3):101468. PMID: 38508144
Neuroblastoma with MYCN amplification (MNA) is a high-risk disease that has a poor survival rate. Neuroblastoma displays cellular heterogeneity, including more differentiated (adrenergic) and more primitive (mesenchymal) cellular states. Here,...
5.
Prutsch N, He S, Berezovskaya A, Durbin A, Dharia N, Maher K, et al.
Cell Rep Med . 2024 Mar; 5(3):101472. PMID: 38508140
Anaplastic large cell lymphoma (ALCL) is an aggressive, CD30 T cell lymphoma of children and adults. ALK fusion transcripts or mutations in the JAK-STAT pathway are observed in most ALCL...
6.
Huang L, Ravi M, Zhang X, Verdejo-Torres O, Shendy N, Nezhady M, et al.
bioRxiv . 2024 Jan; PMID: 38260418
Neuroblastoma remains a formidable challenge in pediatric oncology, representing 15% of cancer-related mortalities in children. Despite advancements in combinatorial and targeted treatments improving survival rates, nearly 50% of patients with...
7.
Lee H, Wright W, Pan M, Low J, Currier D, Fang J, et al.
Nat Commun . 2023 Nov; 14(1):7332. PMID: 37957169
Combination chemotherapy is crucial for successfully treating cancer. However, the enormous number of possible drug combinations means discovering safe and effective combinations remains a significant challenge. To improve this process,...
8.
Zhang Y, Remillard D, Onubogu U, Karakyriakou B, Asiaban J, Ramos A, et al.
Nat Struct Mol Biol . 2023 Jul; 30(8):1160-1171. PMID: 37488358
Transcriptional co-regulators have been widely pursued as targets for disrupting oncogenic gene regulatory programs. However, many proteins in this target class are universally essential for cell survival, which limits their...
9.
Fang J, Singh S, Cheng C, Natarajan S, Sheppard H, Abu-Zaid A, et al.
Nat Commun . 2023 Jul; 14(1):4003. PMID: 37414763
A lack of relevant genetic models and cell lines hampers our understanding of hepatoblastoma pathogenesis and the development of new therapies for this neoplasm. Here, we report an improved MYC-driven...
10.
Weichert-Leahey N, Shi H, Tao T, Oldridge D, Durbin A, Abraham B, et al.
J Clin Invest . 2023 May; 133(10). PMID: 37183825
Childhood neuroblastomas exhibit plasticity between an undifferentiated neural crest-like mesenchymal cell state and a more differentiated sympathetic adrenergic cell state. These cell states are governed by autoregulatory transcriptional loops called...